fashion -WSS

fashion

author：focus 2025-10-01 01:49:33 - browse：4

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Has Bernie Sanders reached the limit of his pharma bullying effort?

explore

WSS

Can gargling with Listerine treat gonorrhea of the mouth?

Is it ever OK for doctors to lie to their patients?

How to bring more disabled researchers into academia

BIO to announce reorganization, senior leaders expected to depart

The problem with charging patients to message their doctors

How a small hospital in rural Puerto Rico survived Hurricane Maria

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

AltruBio raises $225 million to develop ulcerative colitis drug

How one medical school became remarkably diverse

Air quality improving but still lags in Black, Hispanic communities

Alkermes shareholders re

Sepsis can kill a child within hours. Here's how hospitals are fighting back

23andMe had bad news about my health. I wish a person had delivered it

Chemotherapy before breast cancer surgery might fuel metastasis

George Santos makes 1st court appearance after pleading not guilty to 13 counts

UnitedHealth quietly bought dozens of outpatient centers

hotspot

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Most antidepressants don't work on kids, teens, study finds

NEJM study link tiny plastics in blood vessels to heart problems

AI for drug discovery: Experts on separating hype from reality

AI for drug discovery: Experts on separating hype from reality

HHS's proposed rule does nothing to address the climate crisis

leisure time

explore

entertainment

focus